Erken Motor Akılaşmalarını Sunan İspanya'da Parkinson Hastalığı Olan Hastaların Yönetiminde COMT İnhibitörlerinin Gerçek Dünya Kullanımı: REONPARK Çalışmasından Geçici Sonuçlar.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

ObjectiveWe aimed to analyze the real-world use of COMT inhibitors associated with levodopa in patients with Parkinson's disease (PD) who present early fluctuations and to explore whether early COMT inhibition optimizes treatment outcomes.MethodsREONPARK is an ongoing 2-year prospective observational study. We included patients diagnosed with PD who presented signs of end-of-dose motor fluctuations for ResultsSeventy patients were analyzed (mean levodopa dose at inclusion 484.8 mg; duration of motor fluctuations 0.6 years). In all cases, COMT inhibition was initiated with opicapone, and 81% maintained a stable levodopa dose at 3 months. After 3 months of treatment with opicapone, 73.5% and 62.8% of patients improved on CGI-C and PGI-C, respectively. MDS-UPDRS scores improved significantly with a mean change from baseline of -3.3 ± 7.7 (p p ConclusionsIn PD patients with early fluctuations, three months of opicapone reduced the OFF time and improved functional outcomes, suggesting potential benefits in the early stages.

İlgili konular